Mylan Inc. (MYL) Price Target Cut to $48.00
Mylan Inc. (NASDAQ:MYL) had its price target cut by investment analysts at Royal Bank Of Canada from $52.00 to $48.00 in a note issued to investors on Tuesday. The firm presently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price target would suggest a potential upside of 20.09% from the company’s previous close.
Shares of Mylan (NASDAQ:MYL) opened at 39.97 on Tuesday. The stock has a 50 day moving average price of $46.41 and a 200-day moving average price of $45.20. The firm has a market capitalization of $21.38 billion and a price-to-earnings ratio of 25.30. Mylan has a 52 week low of $37.59 and a 52 week high of $55.51.
Mylan (NASDAQ:MYL) last posted its earnings results on Tuesday, August 9th. The company reported $1.16 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.03. The business had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.58 billion. During the same period in the previous year, the firm posted $0.91 earnings per share. The firm’s revenue was up 8.0% compared to the same quarter last year. On average, equities research analysts forecast that Mylan will post $4.97 earnings per share for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/06/mylan-inc-myl-price-target-cut-to-48-00/
Other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP boosted its position in shares of Mylan by 1.2% in the first quarter. Wellington Management Group LLP now owns 45,335,578 shares of the company’s stock worth $2,101,304,000 after buying an additional 551,453 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Mylan by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 10,485,906 shares of the company’s stock valued at $486,022,000 after buying an additional 33,675 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Mylan by 6.9% in the first quarter. Geode Capital Management LLC now owns 3,587,542 shares of the company’s stock valued at $165,967,000 after buying an additional 230,755 shares during the last quarter. Norges Bank bought a new stake in shares of Mylan during the fourth quarter valued at $172,977,000. Finally, Senator Investment Group LP bought a new stake in shares of Mylan during the fourth quarter valued at $166,265,000.
In other Mylan news, CEO Heather M. Bresch sold 100,200 shares of the company’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $50.00, for a total value of $5,010,000.00. Following the completion of the transaction, the chief executive officer now owns 828,318 shares of the company’s stock, valued at approximately $41,415,900. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
A number of other research analysts have also weighed in on MYL. Wells Fargo & Co. set a $44.00 target price on Mylan and gave the stock a “hold” rating in a report on Sunday. Zacks Investment Research raised Mylan from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a report on Tuesday, July 5th. Leerink Swann restated an “outperform” rating and issued a $55.00 price target on shares of Mylan in a research note on Tuesday, August 30th. BTIG Research restated a “buy” rating and issued a $60.00 price target on shares of Mylan in a research note on Tuesday, August 30th. Finally, Evercore ISI restated a “hold” rating and issued a $49.00 price target on shares of Mylan in a research note on Friday, August 26th. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Mylan presently has an average rating of “Buy” and a consensus target price of $54.79.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mylan Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.